These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12141889)

  • 21. Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease.
    Kwak N; Lee MJ; Kang HY; Lee H
    Clin Ther; 2024 Sep; 46(9):670-676. PubMed ID: 39089982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
    Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
    J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease].
    Rudakova AV; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
    Grandas F; Hernández B;
    Eur J Neurol; 2007 Mar; 14(3):282-9. PubMed ID: 17355548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
    Kristiansen IS; Bingefors K; Nyholm D; Isacson D
    Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
    Nissinen H; Kuoppamäki M; Leinonen M; Schapira AH
    Eur J Neurol; 2009 Dec; 16(12):1305-11. PubMed ID: 19570145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.
    Pellicano C; Benincasa D; Giovannelli M; Buttarelli FR; Ruggieri S; Pontieri FE
    Neurol Res; 2009 Feb; 31(1):74-6. PubMed ID: 18691454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
    Gershanik O; Emre M; Bernhard G; Sauer D
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):963-71. PubMed ID: 14499313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entacapone. A review of its use in Parkinson's disease.
    Holm KJ; Spencer CM
    Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
    Jog M; Panisset M; Suchowersky O; Réhel B; Schecter R
    Curr Med Res Opin; 2008 Nov; 24(11):3207-15. PubMed ID: 18922214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
    Ann Neurol; 1997 Nov; 42(5):747-55. PubMed ID: 9392574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.